MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Stoke Therapeutics General and Administrative Expenses 2011-2026 | STOK
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Stoke Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 41.3 M | 38.9 M | 31.9 M | 20.8 M | 11.9 M | 4.41 M | 1.96 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 41.3 M | 1.96 M | 21.6 M |
Quarterly General and Administrative Expenses Stoke Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16 M | 15.3 M | 14.7 M | - | 12.7 M | 13 M | 10.2 M | - | 10.3 M | 10.2 M | 10.2 M | - | 9.94 M | 10.1 M | 9.49 M | - | 8.32 M | 7.93 M | 6.91 M | - | 5.6 M | 5.04 M | 4.52 M | - | 3.32 M | 2.42 M | 2.19 M | - | 1.09 M | 1.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16 M | 1.09 M | 8.29 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
550 M | $ 20.36 | -1.64 % | $ 2.57 B | USA |
 |
Aptorum Group Limited
APM
|
5.41 M | $ 0.81 | -3.83 % | $ 4.42 M | China |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
63.3 M | $ 164.62 | -1.06 % | $ 8.19 B | USA |
 |
AbCellera Biologics
ABCL
|
83.2 M | $ 3.74 | -2.23 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
99.3 M | $ 8.57 | -1.95 % | $ 1.39 B | Britain |
 |
Certara
CERT
|
85.4 M | $ 7.27 | 3.05 % | $ 1.17 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
63.1 M | $ 23.94 | 0.23 % | $ 2.93 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
6.88 M | $ 18.1 | 1.17 % | $ 869 M | USA |
 |
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Eton Pharmaceuticals
ETON
|
18.9 M | $ 17.89 | -1.43 % | $ 459 M | USA |
 |
Exelixis
EXEL
|
519 M | $ 40.99 | -0.1 % | $ 11.1 B | USA |
 |
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
12.8 M | $ 26.27 | -2.2 % | $ 703 M | USA |
 |
Galapagos NV
GLPG
|
141 M | $ 33.2 | -2.61 % | $ 2.69 B |  Belgium |
 |
Greenwich LifeSciences
GLSI
|
3.06 M | $ 27.98 | 2.15 % | $ 364 M | USA |
 |
Galecto
GLTO
|
12.7 M | $ 29.63 | -1.39 % | $ 787 M |  Danmark |
 |
Genmab A/S
GMAB
|
661 M | $ 27.76 | -6.37 % | $ 17.6 B | Danmark |
 |
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
55.1 M | $ 1.0 | -1.47 % | $ 73.4 M | USA |
 |
Halozyme Therapeutics
HALO
|
207 M | $ 69.4 | -0.64 % | $ 8.32 B | USA |
 |
Hoth Therapeutics
HOTH
|
4.97 M | $ 1.01 | -0.98 % | $ 6.44 M | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | Canada |
 |
Harmony Biosciences Holdings
HRMY
|
153 M | $ 28.63 | -0.95 % | $ 1.65 B | USA |
 |
AgeX Therapeutics
AGE
|
9.33 M | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
2.22 M | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
Immuron Limited
IMRN
|
3.52 M | $ 0.75 | -0.69 % | $ 6.46 M |  Australia |
|
Immatics N.V.
IMTX
|
33.8 M | $ 9.95 | -0.4 % | $ 626 M | Germany |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Immunic
IMUX
|
21.2 M | $ 1.12 | 5.19 % | $ 174 M | USA |
 |
Agenus
AGEN
|
78.7 M | $ 3.24 | -3.14 % | $ 1.16 M | USA |
 |
Immunovant
IMVT
|
77.2 M | $ 27.24 | -1.84 % | $ 4.13 B | USA |
 |
Inhibrx
INBX
|
29.4 M | $ 76.35 | -1.47 % | $ 3.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M |  Israel |
 |
InMed Pharmaceuticals
INM
|
369 K | $ 0.78 | -4.88 % | $ 1.91 M | Canada |
 |
INmune Bio
INMB
|
9.62 M | $ 1.39 | 4.66 % | $ 25 M | USA |
 |
Insmed Incorporated
INSM
|
701 M | $ 147.23 | 0.62 % | $ 29.3 B | USA |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |